IrFN, a nitrone-functionalized, mitochondria-targeted iridium(III) complex, was the first anticancer iridium complex reported to kill cancer cells through ferroptosis: it accumulates in mitochondria of A2780 ovarian carcinoma cells, produces massive transcriptional upregulation of heme oxygenase-1 (HMOX1, about 56-fold at the mRNA level), releases labile iron, and drives iron-dependent lipid peroxidation, with an IC50IC_{50} of 0.69 µM, roughly 25-fold below cisplatin in the same assay. The original study established HMOX1 upregulation as partially necessary and sufficient (overexpression phenocopy and partial siRNA protection), but left the causal chain undefined. This problem asks for (i) the molecular pathway connecting mitochondrial iridium accumulation to HMOX1 transcriptional activation and iron dysregulation, and whether mitochondrial localization is causally required; and (ii) the determinants of the cell-line-selective response, in which A2780 cells mount a strong HMOX1/ferroptosis response while other tested cancer and non-malignant cells respond weakly or not at all. The in vivo antitumor efficacy, systemic toxicity, and therapeutic index of IrFN itself are not part of the mandatory problem; in vivo validation is at most an optional translational extension. Literature from 2019 to 2026 has validated ferroptosis induction, in vivo feasibility, and apoptosis-resistance override for related iridium complexes, and delineated KEAP1-NRF2-HMOX1 signaling for small-molecule ferroptosis inducers, but never for a mitochondria-targeted metallodrug, leaving the IrFN-specific mechanistic core open.

Background

Ferroptosis is a regulated, non-apoptotic form of cell death defined by iron-dependent accumulation of lipid hydroperoxides in cellular membranes (Dixon et al., 2012). It can be triggered by disabling glutathione peroxidase 4 (GPX4), the enzyme that detoxifies membrane lipid peroxides (the canonical route exploited by the experimental lethal compounds erastin and RSL3), or by overloading cells with labile iron (the redox-active, weakly chelated Fe(II) pool) that fuels peroxide-propagating Fenton chemistry. Heme oxygenase-1 (HMOX1, also HO-1) is an inducible enzyme that degrades heme into biliverdin, carbon monoxide, and ferrous iron; each heme molecule degraded releases one Fe(II) into the labile iron pool. HMOX1 transcription is normally held low by the repressor BACH1 and is strongly induced when the transcription factor NRF2 (NFE2L2) escapes its cytosolic adaptor KEAP1 and binds antioxidant response elements in the HMOX1 promoter. Hyperactivated HMOX1 can therefore convert a drug-derived stress signal into labile-iron release and ferroptotic lipid peroxidation, a so-called noncanonical ferroptosis route demonstrated for the small molecules BAY 11-7085 (Chang et al., 2018) and withaferin A, which covalently targets KEAP1 to hyperactivate NRF2-HMOX1 signaling (Hassannia et al., 2018).

Metal complexes (metallodrugs) are a major class of anticancer agents; the clinical platinums kill cells mainly through DNA damage and apoptosis. Because apoptosis resistance is a principal mode of treatment failure, non-apoptotic death pathways such as ferroptosis have become design targets for new metallodrugs, and mitochondria are attractive sites of action given their central roles in redox and iron metabolism. Within this landscape, Wang and co-workers (Science China Chemistry, 2020) reported IrFN, a nitrone-functionalized (nitrone: an N-oxide imine group widely used to trap radical species), mitochondria-targeted iridium(III) complex, the first anticancer iridium(III) complex shown to induce ferroptosis. In A2780 human ovarian carcinoma cells, IrFN was about 25-fold more potent than cisplatin (IC50IC_{50}, the half-maximal inhibitory concentration, of 0.69 µM versus 17.08 µM); approximately 87% of cellular iridium was recovered in the mitochondrial fraction by subcellular fractionation and ICP-MS (inductively coupled plasma mass spectrometry, an elemental-quantification technique); and label-free quantitative proteomics identified HMOX1 as the most strongly upregulated protein (9.8-fold among 47 differentially expressed proteins, and about 56-fold at the mRNA level by quantitative RT-PCR). Forced HMOX1 overexpression phenocopied IrFN treatment (decreased viability; increased labile iron, imaged with the Fe(II)-responsive probe FeRhonox-1; increased reactive oxygen species (ROS) and lipid peroxidation; upregulation of LC3, a marker of autophagy, of the iron-storage protein ferritin light chain FTL, and of NCOA4, the cargo receptor for ferritinophagy, the autophagic degradation of ferritin), and this death was rescued by the iron chelator deferoxamine (DFO) and by ferrostatin-1, a radical-trapping inhibitor of ferroptosis. Conversely, siRNA-mediated HMOX1 knockdown (about 50% reduction) significantly but only partially protected cells from IrFN. The source also reports potent antiproliferative activity against a variety of cancer cells, with A2780 especially responsive, but does not explain this differential response. The study thus established HMOX1 upregulation as partially necessary and sufficient for IrFN-induced ferroptosis, while remaining silent on the two issues that define the present problem: how mitochondrial iridium accumulation is transduced into a ~56-fold HMOX1 transcriptional response, and why this response is so much stronger in A2780 than in the other tested cell lines.

Problem Statement

Determine and validate the mechanism of ferroptosis induction by the mitochondria-targeted iridium(III) complex IrFN, as two linked objectives:

(1) Mechanism of HMOX1 activation. Identify the molecular pathway by which mitochondrial accumulation of IrFN in A2780 cells produces strong transcriptional activation of HMOX1 (about 56-fold mRNA induction) and downstream dysregulation of iron homeostasis: which signaling events connect iridium-loaded mitochondria to the HMOX1 promoter (candidate routes include KEAP1-NRF2 antioxidant-response signaling, BACH1 derepression, mitochondrial retrograde or integrated-stress signaling, or a direct transcriptional-perturbation target), and is mitochondrial localization of IrFN causally required for this activation?

(2) Determinants of cell-line selectivity. Identify the molecular determinants - for example differences in KEAP1/NRF2 or BACH1 status, heme turnover, ferritin and labile-iron pools, or baseline antioxidant capacity - that make A2780 cells mount a strong HMOX1/ferroptosis response to IrFN while the other tested cancer cell lines and non-malignant cells respond weakly or not at all (the source reports potent antiproliferative activity against a variety of cancer cells, especially A2780, without explaining the differential response), and provide causal evidence for the identified determinants.

A complete answer provides causal evidence for the signaling pathway linking mitochondrial IrFN accumulation to HMOX1 transcriptional activation and iron dysregulation, together with causal evidence on whether mitochondrial localization of IrFN is required for that activation, in (1), and a mechanistic, causally supported explanation of the cell-line-selective response in (2); resolving only one of the two components leaves the problem open. The in vivo antitumor efficacy, systemic toxicity, and therapeutic index of IrFN itself are not required for a complete answer; in vivo validation is at most an optional translational extension.

References

  1. Wang X, Chen F, Zhang J, Sun J, Zhao X, Zhu Y, Wei W, Zhao J, Guo Z. A ferroptosis-inducing iridium(III) complex. Science China Chemistry 63(1):65-72, 2020. DOI: 10.1007/s11426-019-9577-3. https://doi.org/10.1007/s11426-019-9577-3 (published online 2019-09-17; issue dated January 2020)
  2. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell 149(5):1060-1072, 2012. DOI: 10.1016/j.cell.2012.03.042. https://doi.org/10.1016/j.cell.2012.03.042
  3. Chang LC, Chiang SK, Chen SE, Yu YL, Chou RH, Chang WC. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Letters 416:124-137, 2018. DOI: 10.1016/j.canlet.2017.12.025. https://doi.org/10.1016/j.canlet.2017.12.025
  4. Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Bayir H, Abhari BA, Angeli JPF, Choi SM, Meul E, Heyninck K, Declerck K, Chirumamilla CS, Lahtela-Kakkonen M, Van Camp G, Krysko DV, Ekert PG, Fulda S, De Geest BG, Conrad M, Kagan VE, Vanden Berghe W, Vandenabeele P, Vanden Berghe T. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. Journal of Clinical Investigation 128(8):3341-3355, 2018. DOI: 10.1172/jci99032. https://doi.org/10.1172/jci99032
  5. Li S, Yuan H, Chen Y, Guo Z. Metal complexes induced ferroptosis for anticancer therapy. Fundamental Research 3(4):525-528, 2023. DOI: 10.1016/j.fmre.2022.10.001. https://doi.org/10.1016/j.fmre.2022.10.001
  6. Yuan H, Han Z, Chen Y, Qi F, Fang H, Guo Z, Zhang S, He W. Ferroptosis Photoinduced by New Cyclometalated Iridium(III) Complexes and Its Synergism with Apoptosis in Tumor Cell Inhibition. Angewandte Chemie International Edition 60(15):8174-8181, 2021. DOI: 10.1002/anie.202014959. https://doi.org/10.1002/anie.202014959
  7. Zhao X, Zhang J, Zhang W, Guo Z, Wei W, Wang X, Zhao J. A chiral fluorescent Ir(iii) complex that targets the GPX4 and ErbB pathways to induce cellular ferroptosis. Chemical Science 14(5):1114-1122, 2023. DOI: 10.1039/d2sc06171f. https://doi.org/10.1039/d2sc06171f
  8. Zhu L, Wang X, Tian T, Chen Y, Du W, Wei W, Zhao J, Guo Z, Wang X. A Λ-Ir(iii)-phenylquinazolinone complex enhances ferroptosis by selectively inhibiting metallothionein-1. Chemical Science 15(27):10499-10507, 2024. DOI: 10.1039/d4sc00422a. https://doi.org/10.1039/d4sc00422a
  9. Li J, Gao G, Ouyang W, Huang J, Liu H, Li J. A rhodamine-coordinated iridium complex to overcome cisplatin-resistant cancer via regulating mitochondrial function triggered apoptosis and ferroptosis. Redox Biology 81:103536, 2025. DOI: 10.1016/j.redox.2025.103536. https://doi.org/10.1016/j.redox.2025.103536
  10. Wang WJ, Ling YY, Zhong YM, Li ZY, Tan CP, Mao ZW. Ferroptosis-Enhanced Cancer Immunity by a Ferrocene-Appended Iridium(III) Diphosphine Complex. Angewandte Chemie International Edition 61(16):e202115247, 2022. DOI: 10.1002/anie.202115247. https://doi.org/10.1002/anie.202115247
  11. Mukherjee S, Ghosh S, Renuga Devi M, Roy S, Saha Roy S, Acharya M, Kumar BK, Mukherjee A. Peroxiredoxin Depletion and Oxidative Stress by Cyclometalated Ir(III)-Isatin Complexes Renders Ferroptosis and Autophagic Cell Death in Triple-Negative Breast Cancer. Journal of Medicinal Chemistry 68(20):21201-21223, 2025. DOI: 10.1021/acs.jmedchem.5c01150. https://doi.org/10.1021/acs.jmedchem.5c01150
  12. Štarha P, Friedecká J, Héžová R, Bárta O, Jarošová R, Mašek J, Nemec I, Milde D, Novobilský A, Novotný L, Ondruš J, Šterbinská S, Straková N, Lenobel R, Hošek J. Mechanistic Exploration of Half-Sandwich Iridium(III) Anticancer Compounds through Integrated Cellular, Proteomic, and In Vivo Analyses. Journal of Medicinal Chemistry 69(13):15166-15190, 2026. DOI: 10.1021/acs.jmedchem.5c03448. https://doi.org/10.1021/acs.jmedchem.5c03448
  13. Ma Y, Zhang S, Zhang D, Hua Z, Li Z. DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes. Redox Report 31(1):2702136, 2026. DOI: 10.1080/13510002.2026.2702136. https://doi.org/10.1080/13510002.2026.2702136
  14. Ahmed B, Salaun D, Jordan JB, Daulat A, Pastorello C, Brito T, Yang Y, Josselin E, Byrne D, Betzi S, Pelletier A, Vernerey J, Ferreira L, Castellano R, Audebert S, Camoin L, Pane A, Bechara C, Borg JP, Modesti M, Lignitto L. CRL2-FEM1B uses heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer. Molecular Cell 86(10):1993-2011.e10, 2026. DOI: 10.1016/j.molcel.2026.04.008. https://doi.org/10.1016/j.molcel.2026.04.008
  15. de Souza I, Marques Andrade IA, Porto Freitas F, da Silva Teixeira AB, Clares Ramalho MC, Almeida Lima K, Ferreira dos Santos A, Schmitz W, Fazeli G, Reily Rocha CR, Friedmann Angeli JP. HMOX1 controls a heme-ferritin switch that protects cells from ferroptosis. bioRxiv preprint, 2025. DOI: 10.1101/2025.10.14.682408. https://doi.org/10.1101/2025.10.14.682408
  16. Zhou YC, Zhao TK, Tao SM, Wang P, Guan YC, Yang KP, Chen SQ, Pu XY. Recent Progress in Ferroptosis Induced Tumor Cell Death by Anti-tumor Metallic complexes. Chemistry - An Asian Journal 19(3):e202301020, 2024. DOI: 10.1002/asia.202301020. https://doi.org/10.1002/asia.202301020
  17. Su Y, Liu B, Wang B, Chan L, Xiong C, Lu L, Zhang X, Zhan M, He W. Progress and Challenges in Tumor Ferroptosis Treatment Strategies: A Comprehensive Review of Metal Complexes and Nanomedicine. Small 20(25):2310342, 2024. DOI: 10.1002/smll.202310342. https://doi.org/10.1002/smll.202310342